Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 895 of 1,261
  1. US 8329876

    Thioester-terminated water soluble polymers and method of modifying the N-terminus of a polypeptide therewith

    Nektar Therapeutics · Granted Dec 11, 2012 · Expires Dec 6, 2032

    granted
  2. US 8329900

    Dipeptidyl peptidase inhibitors

    Takeda Pharmaceutical Company Limited · Granted Dec 11, 2012 · Expires Dec 6, 2032

    granted
  3. US 8329924

    Compounds and methods for the treatment or prevention of Flavivirus infections

    Vertex Pharmaceuticals (Canada) Incorporated · Granted Dec 11, 2012 · Expires Dec 6, 2032

    granted
  4. US 8329181

    Methods for treating B-cell lymphoma by administering an anti-CD20 antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 11, 2012 · Expires Dec 6, 2032

    granted
  5. US 8328785

    Use of nanoparticles in the photodynamic treatment of tumors

    The Board of Regents of the University of Texas System · Granted Dec 11, 2012 · Expires Dec 6, 2032

    granted
  6. BR PI0614453

    método de redução de cululite indesejada em áreas seletivas de um organismo e mistura fotossensibilizante

    CERAMOPTEC IND INC [US] · Granted Dec 11, 2012 · Expires Dec 6, 2032

    granted
  7. US 8324242

    Modulators of ATP-binding cassette transporters

    Vertex Pharmaceuticals Incorporated · Granted Dec 4, 2012 · Expires Nov 29, 2032

    granted
  8. US 8323634

    Stable formulations of highly concentrated recombinant human albumin-human granulocyte colony stimulating factor

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Dec 4, 2012 · Expires Nov 29, 2032

    granted
  9. US 8323662

    Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein

    IMMUNE DESIGN CORP. · Granted Dec 4, 2012 · Expires Nov 29, 2032

    granted
  10. US 8323665

    Ricin A chain mutants lacking enzymatic activity as vaccines to protect against aerosolized ricin

    The Board of Regents of the University of Texas System · Granted Dec 4, 2012 · Expires Nov 29, 2032

    granted
  11. US 8323670

    Topical compositions of opioid antagonists and methods for treating skin conditions therewith

    Ak Kimya Ithalat-Ihracat Ve Sanayii A.S. · Granted Dec 4, 2012 · Expires Nov 29, 2032

    granted
  12. US 8324155

    Quinoxaline-containing compounds as hepatitis C virus inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Dec 4, 2012 · Expires Nov 29, 2032

    granted
  13. US 8323671

    Prolyl hydroxylase inhibitors and methods of use

    Akebia Therapeutics, Inc. · Granted Dec 4, 2012 · Expires Nov 29, 2032

    granted
  14. US 8324203

    Azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Dec 4, 2012 · Expires Nov 29, 2032

    granted
  15. US 8324201

    Pyrazinooxazepine derivatives

    Takeda Pharmaceutical Company Limited · Granted Dec 4, 2012 · Expires Nov 29, 2032

    granted
  16. US 8324178

    Method of treatment using alpha-1-adrenergic agonist compounds

    The Regents of the University of California · Granted Dec 4, 2012 · Expires Nov 29, 2032

    granted
  17. US 8322588

    Structure containing wound treatment material

    Covidien LP · Granted Dec 4, 2012 · Expires Nov 29, 2032

    granted
  18. US 8323632

    Multi-arm polypeptide-poly(ethylene glycol) block copolymers as drug delivery vehicles

    Nektar Therapeutics · Granted Dec 4, 2012 · Expires Nov 29, 2032

    granted
  19. US 8323617

    Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid

    ANIKA THERAPEUTICS, INC. · Granted Dec 4, 2012 · Expires Nov 29, 2032

    granted
  20. US 8324169

    VEGF-activated ligands

    The Regents of the University of California · Granted Dec 4, 2012 · Expires Nov 29, 2032

    granted
  21. US 8323906

    Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer

    The Board of Regents of the University of Texas System · Granted Dec 4, 2012 · Expires Nov 29, 2032

    granted
  22. US 8323635

    Methods of using interleukin-1 receptor antagonist as a myeloprotective agent

    GENERAL REGENERATIVES, LTD. · Granted Dec 4, 2012 · Expires Nov 29, 2032

    granted
  23. US 8324171

    Ophthalmic compositions containing diglycine

    BURKE SUSAN E [US] · Granted Dec 4, 2012 · Expires Nov 29, 2032

    granted
  24. US 8324395

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Granted Dec 4, 2012 · Expires Nov 29, 2032

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.